191 related articles for article (PubMed ID: 34855287)
1. Synopsis of a clinical practice guideline for pancreatic ductal adenocarcinoma with peritoneal dissemination in Japan; Japan Peritoneal Malignancy Study Group.
Satoi S; Takahara N; Fujii T; Isayama H; Yamada S; Tsuji Y; Miyato H; Yamaguchi H; Yamamoto T; Hashimoto D; Yamaki S; Nakai Y; Saito K; Baba H; Watanabe T; Ishii S; Hayashi M; Kurimoto K; Shimada H; Kitayama J
J Hepatobiliary Pancreat Sci; 2022 Jun; 29(6):600-608. PubMed ID: 34855287
[TBL] [Abstract][Full Text] [Related]
2. Clinical practice guideline for the treatment of malignant ascites: section summary in Clinical Practice Guideline for peritoneal dissemination (2021).
Matsusaki K; Aridome K; Emoto S; Kajiyama H; Takagaki N; Takahashi T; Tsubamoto H; Nagao S; Watanabe A; Shimada H; Kitayama J
Int J Clin Oncol; 2022 Jan; 27(1):1-6. PubMed ID: 34800177
[TBL] [Abstract][Full Text] [Related]
3. Clinical Practice Guidelines for Pancreatic Cancer 2022 from the Japan Pancreas Society: a synopsis.
Okusaka T; Nakamura M; Yoshida M; Kitano M; Ito Y; Mizuno N; Hanada K; Ozaka M; Morizane C; Takeyama Y;
Int J Clin Oncol; 2023 Apr; 28(4):493-511. PubMed ID: 36920680
[TBL] [Abstract][Full Text] [Related]
4. The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review.
Brind'Amour A; Webb M; Parapini M; Sidéris L; Segedi M; Chung SW; Chartier-Plante S; Dubé P; Scudamore CH; Kim PTW
Clin Exp Metastasis; 2021 Apr; 38(2):187-196. PubMed ID: 33486670
[TBL] [Abstract][Full Text] [Related]
5. Clinical Practice Guidelines for Pancreatic Cancer 2019 From the Japan Pancreas Society: A Synopsis.
Okusaka T; Nakamura M; Yoshida M; Kitano M; Uesaka K; Ito Y; Furuse J; Hanada K; Okazaki K;
Pancreas; 2020 Mar; 49(3):326-335. PubMed ID: 32132516
[TBL] [Abstract][Full Text] [Related]
6. Autotaxin in ascites promotes peritoneal dissemination in pancreatic cancer.
Jinno N; Yoshida M; Hayashi K; Naitoh I; Hori Y; Natsume M; Kato A; Kachi K; Asano G; Atsuta N; Sahashi H; Kataoka H
Cancer Sci; 2021 Feb; 112(2):668-678. PubMed ID: 33053268
[TBL] [Abstract][Full Text] [Related]
7. Is surgical resection justified for pancreatic ductal adenocarcinoma with distant abdominal organ metastasis? A position paper by experts in pancreatic surgery at the Joint Meeting of the International Association of Pancreatology (IAP) & the Japan Pancreas Society (JPS) 2022 in Kyoto.
Hashimoto D; Satoi S; Fujii T; Sho M; He J; Hackert T; Del Chiaro M; Jang JY; Gulla A; Yoon YS; Shan YS; Lou W; Valente R; Furuse J; Oba A; Nagai M; Terai T; Tanaka H; Sakai A; Yamamoto T; Yamaki S; Matsumoto I; Murakami Y; Takaori K; Takeyama Y
Pancreatology; 2023 Sep; 23(6):682-688. PubMed ID: 37507301
[TBL] [Abstract][Full Text] [Related]
8. Multicenter Phase II Study of Intravenous and Intraperitoneal Paclitaxel With S-1 for Pancreatic Ductal Adenocarcinoma Patients With Peritoneal Metastasis.
Satoi S; Fujii T; Yanagimoto H; Motoi F; Kurata M; Takahara N; Yamada S; Yamamoto T; Mizuma M; Honda G; Isayama H; Unno M; Kodera Y; Ishigami H; Kon M
Ann Surg; 2017 Feb; 265(2):397-401. PubMed ID: 28059968
[TBL] [Abstract][Full Text] [Related]
9. Clinical Practice Guidelines for Pancreatic Cancer 2016 From the Japan Pancreas Society: A Synopsis.
Yamaguchi K; Okusaka T; Shimizu K; Furuse J; Ito Y; Hanada K; Shimosegawa T; Okazaki K;
Pancreas; 2017; 46(5):595-604. PubMed ID: 28426492
[TBL] [Abstract][Full Text] [Related]
10. Proteomic Analysis of Malignant Ascites From Patients With Pancreatic Ductal Adenocarcinoma.
Kitamura F; Miyata T; Uemura N; Uchihara T; Imai K; Hayashi H; Yamashita YI; Matsusaki K; Ishimoto T; Baba H
Anticancer Res; 2021 Jun; 41(6):2895-2900. PubMed ID: 34083280
[TBL] [Abstract][Full Text] [Related]
11. Prognostic importance of peritoneal washing cytology in patients with otherwise resectable pancreatic ductal adenocarcinoma who underwent pancreatectomy: A nationwide, cancer registry-based study from the Japan Pancreas Society.
Tsuchida H; Fujii T; Mizuma M; Satoi S; Igarashi H; Eguchi H; Kuroki T; Shimizu Y; Tani M; Tanno S; Tsuji Y; Hirooka Y; Masamune A; Mizumoto K; Itoi T; Egawa S; Kodama Y; Hamada S; Unno M; Yamaue H; Okazaki K;
Surgery; 2019 Dec; 166(6):997-1003. PubMed ID: 31445763
[TBL] [Abstract][Full Text] [Related]
12. Survival benefit of intravenous and intraperitoneal paclitaxel with S-1 in pancreatic ductal adenocarcinoma patients with peritoneal metastasis: a retrospective study in a single institution.
Satoi S; Yanagimoto H; Yamamoto T; Hirooka S; Yamaki S; Kosaka H; Inoue K; Hashimoto Y; Matsui Y; Kon M
J Hepatobiliary Pancreat Sci; 2017 May; 24(5):289-296. PubMed ID: 28301088
[TBL] [Abstract][Full Text] [Related]
13. Association between primary origin (head, body and tail) of metastasised pancreatic ductal adenocarcinoma and oncologic outcome: A population-based analysis.
Mackay TM; van Erning FN; van der Geest LGM; de Groot JWB; Haj Mohammad N; Lemmens VE; van Laarhoven HW; Besselink MG; Wilmink JW;
Eur J Cancer; 2019 Jan; 106():99-105. PubMed ID: 30476732
[TBL] [Abstract][Full Text] [Related]
14. MiR-194-5p in Pancreatic Ductal Adenocarcinoma Peritoneal Washings is Associated with Peritoneal Recurrence and Overall Survival in Peritoneal Cytology-Negative Patients.
Kubo H; Hiroshima Y; Mori R; Saigusa Y; Murakami T; Yabushita Y; Sawada Y; Homma Y; Kumamoto T; Matsuyama R; Endo I
Ann Surg Oncol; 2019 Dec; 26(13):4506-4514. PubMed ID: 31489551
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of intraoperative peritoneal washing cytology for patients with potentially resectable pancreatic ductal adenocarcinoma.
Hoshimoto S; Hishinuma S; Shirakawa H; Tomikawa M; Ozawa I; Hoshi N; Hoshi S; Hirabayashi K; Ogata Y
Pancreatology; 2017; 17(1):109-114. PubMed ID: 27840175
[TBL] [Abstract][Full Text] [Related]
16. White paper on pancreatic ductal adenocarcinoma from society of abdominal radiology's disease-focused panel for pancreatic ductal adenocarcinoma: Part I, AJCC staging system, NCCN guidelines, and borderline resectable disease.
Kulkarni NM; Soloff EV; Tolat PP; Sangster GP; Fleming JB; Brook OR; Wang ZJ; Hecht EM; Zins M; Bhosale PR; Arif-Tiwari H; Mannelli L; Kambadakone AR; Tamm EP
Abdom Radiol (NY); 2020 Mar; 45(3):716-728. PubMed ID: 31748823
[TBL] [Abstract][Full Text] [Related]
17. Intraperitoneal Paclitaxel Treatment for Patients with Pancreatic Ductal Adenocarcinoma with Peritoneal Dissemination Provides a Survival Benefit.
Yamamoto T; Satoi S; Yamaki S; Hashimoto D; Ishida M; Ikeura T; Hirooka S; Matsui Y; Boku S; Nakayama S; Nakamaru K; Shibata N; Katsushima U; Sekimoto M
Cancers (Basel); 2022 Mar; 14(5):. PubMed ID: 35267661
[TBL] [Abstract][Full Text] [Related]
18. Interferon γ improves the vaccination potential of oncolytic parvovirus H-1PV for the treatment of peritoneal carcinomatosis in pancreatic cancer.
Grekova SP; Aprahamian M; Daeffler L; Leuchs B; Angelova A; Giese T; Galabov A; Heller A; Giese NA; Rommelaere J; Raykov Z
Cancer Biol Ther; 2011 Nov; 12(10):888-95. PubMed ID: 22024742
[TBL] [Abstract][Full Text] [Related]
19. Development and Biological Analysis of a Novel Orthotopic Peritoneal Dissemination Mouse Model Generated Using a Pancreatic Ductal Adenocarcinoma Cell Line.
Yanagihara K; Kubo T; Mihara K; Kuwata T; Ochiai A; Seyama T; Yokozaki H
Pancreas; 2019 Mar; 48(3):315-322. PubMed ID: 30747829
[TBL] [Abstract][Full Text] [Related]
20. Health Disparities Impact Expected Treatment of Pancreatic Ductal Adenocarcinoma Nationally.
Lutfi W; Zenati MS; Zureikat AH; Zeh HJ; Hogg ME
Ann Surg Oncol; 2018 Jul; 25(7):1860-1867. PubMed ID: 29691733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
